about
Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsPassive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNAPre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaquesNeutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaquesState of the art in anti-cancer mAbs.Bovine leukemia virus becomes established in dairy herds before the first lactation.Short communication: Relationship between the level of bovine leukemia virus antibody and provirus in blood and milk of cows from a naturally infected herd.Validation of an r3AB1-FMDV-NSP ELISA to distinguish between cattle infected and vaccinated with foot-and-mouth disease virus.Unpasteurized milk from the bulk tank used for calf-feeding might increase incidence of BLV in dairy farms.Quantification of bovine leukemia virus proviral DNA using a low-cost real-time polymerase chain reaction.Inter-laboratory comparison of six real time polymerase chain reaction assays for detection of bovine leukemia virus proviral DNA.[New therapy with monoclonal antibodies would allow to eliminate the reservoir of human immunodeficiency virus (HIV-1)].Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1Short communication: Bovine leukemia virus infection in adult cows does not interfere with foot-and-mouth disease vaccinationDirect role of the C-C motif chemokine receptor 2/monocyte chemoattractant protein 1 system in the feline cumulus oocyte complexSpontaneous virus reactivation in cattle chronically infected with bovine leukemia virusLong-lasting HIV suppression by combined immunotherapyArgentina's subpar investment in science
P50
Q28732043-CAB7C8A7-2750-4ED4-BA9B-0BE4E7737858Q34185625-739CCCD4-6947-4A11-ABB0-3FEF8496449BQ34712503-CA1DAA3E-5D9D-4994-8F84-E5B80B6F1D3EQ36286484-A30130D6-BF09-4319-962F-66EFFBCFE404Q37252831-6F019F00-0A79-400B-A9F0-9CE566381695Q37655585-F62CA719-8DFB-4D19-81FE-79137084190FQ40594354-308009D5-445B-4B33-AE51-C67187D90302Q40692607-B074DE2A-2879-4F56-AA50-10D59CA58460Q45363032-D08B71F0-BC40-4976-A16D-215F9AB45CD5Q46106120-D87C189C-248C-4389-84C0-16EF1221AE1EQ54092194-75BD5A78-2C13-48C4-B2B7-E8B54DCC3775Q54233019-410EE8D6-1EA4-4D5C-B653-E2AB790D4D3AQ54443062-8288F074-F76E-4395-B907-C328B2C4D9FEQ57093617-35A6B087-EF5D-4061-B42A-3EFF4106A64BQ57478446-69BCCB88-5F28-4D1B-92A4-1257D16FA203Q58613512-2F323E90-F5C7-4E47-B2B3-22EF25308727Q64053296-973688BA-8498-4313-8610-FA2846D0DF56Q90346145-E4EFA6F0-A300-460E-AA48-778C36BD6332Q91595273-7BBC73F7-3CC3-4C03-9D71-5B7D7ED1246C
P50
description
researcher ORCID ID = 0000-0002-1311-060X
@en
wetenschapper
@nl
name
Juan Pablo Jaworski
@ast
Juan Pablo Jaworski
@en
Juan Pablo Jaworski
@es
Juan Pablo Jaworski
@nl
type
label
Juan Pablo Jaworski
@ast
Juan Pablo Jaworski
@en
Juan Pablo Jaworski
@es
Juan Pablo Jaworski
@nl
prefLabel
Juan Pablo Jaworski
@ast
Juan Pablo Jaworski
@en
Juan Pablo Jaworski
@es
Juan Pablo Jaworski
@nl
P106
P21
P31
P496
0000-0002-1311-060X